BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company deeply integrated in guiding patient care, has launched Insight Analytics™ reports that support provider organizations delivering improved care, both individually and on a population level, for a range of high-risk health conditions. The reports, which reflect LabCorp’s deep analytical expertise, combine national laboratory test values with patient demographics to help identify high-risk patients, close care gaps, and support the implementation of more effective treatment practices. Healthcare organizations and public health agencies can use the reports to implement more effective treatment practices to reduce risk levels for co-morbidities including COVID-19, reducing serious complications and the need for hospitalization.
Insight Analytics reports are available for conditions such as diabetes and chronic kidney disease (CKD). These conditions present significant risks on their own, are health co-morbidities for other diseases, and also indicate heightened risk for serious complications from COVID-19. Reports are also available for other conditions that impact hospitalizations, including community acquired methicillin-resistant Staphylococcus aureus (MRSA). Insight Analytics reports are currently being used by organizations to support their care for patients who may be at greater risk due to COVID-19.
“LabCorp’s new Insight Analytics reports can help clinicians and health officials be better informed and provide more focused patient engagement, supporting better outcomes,” says Dot Adcock, M.D., LabCorp Diagnostics’ chief medical officer. “Laboratory testing and the vital information it provides is more important now than ever before, and is a central part of our mission to improve health and improve lives.”
“Laboratory testing influences a significant percentage of clinical decisions and plays an important role in improving care for patients with common, high-risk conditions,” says Brian Caveney, M.D., chief medical officer and president of LabCorp Diagnostics. “The past several months have demonstrated very clearly that accurate and high-quality diagnostics are vital. Our analytical depth, combined expertise in diagnostics and drug development, and tools like our Insight Analytics reports, show that LabCorp is uniquely positioned to help clinicians address pervasive health challenges, including our current COVID-19 health crisis.”
More information about the Insight Analytics reports is available at www.labcorp.com/labcorp-insight-analytics. Also available there are Insight Analytics Nationwide Snapshots for diabetes prevalence and antibiotic resistance in bladder infections. These Snapshot reports illustrate statistically relevant disease trends on a national and state level using LabCorp data.
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019.
Forward Looking Statement
This press release contains forward-looking statements, including but not limited to statements with respect to the Company’s future operations, Insight Analytics and Insight Analytics Nationwide Snapshots report offerings, and opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the impact of the COVID-19 pandemic on our business and financial condition as well as on general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, the effect of public opinion on the Company’s reputation, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, the number of revenue days in a financial period, personnel costs, and the effect of exchange rate fluctuations, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.